US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter releasing agent
pharma · Stargardt Disease · Muscle Relaxation · ELTP
ELITE PHARMACEUTICALS INC
ELITE PHARMACEUTICALS INC /NV/
ELITE PHARMACEUTICALS INC drug portfolio — 24 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Northvale, USA HQ
1996 Founded
64 Employees
Public company Type
ELTP · NYSE Ticker
Company details
- Status
- Public
- HQ
- Northvale, USA
- Founded
- 1996
- Employees
- 64
- Programs
- 8
- Drugs
- 24
- Patents
- 26
ELITE PHARMACEUTICALS INC pipeline
Portfolio lens on 24 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
ELITE PHARMACEUTICALS INC drug portfolio — 24 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
asenapine
Nervous system (N05)US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
Development asset linked to ELITE PHARMACEUTICALS INC in public FDA and regional records.
-
Development asset linked to ELITE PHARMACEUTICALS INC in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: Ryanodine receptor 1.
- Target
- Ryanodine receptor 1
- Mechanism
- Ryanodine receptor 3 antagonist
-
US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.
- Target
- Voltage-gated L-type calcium channel
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Synaptic vesicular amine transporter inhibitor
-
US regulatory status: approved. Molecular target: D2-like dopamine receptor.
- Target
- D2-like dopamine receptor
- Mechanism
- D2-like dopamine receptor antagonist
-
Development asset linked to ELITE PHARMACEUTICALS INC in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Mu-type opioid receptor.
- Target
- Mu-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
naltrexone
Alimentary tract and metabolism (A08)US regulatory status: approved. Molecular target: Opioid receptors; mu/kappa/delta.
- Target
- Opioid receptors; mu/kappa/delta
- Mechanism
- Opioid receptors; mu/kappa/delta antagonist
-
US regulatory status: approved. Molecular target: Opioid receptors; mu/kappa/delta.
- Target
- Opioid receptors; mu/kappa/delta
- Mechanism
- Opioid receptors; mu/kappa/delta antagonist
-
orlistat
Alimentary tract and metabolism (A08)US regulatory status: approved. Molecular target: Gastric triacylglycerol lipase.
- Target
- Gastric triacylglycerol lipase
- Mechanism
- Pancreatic lipase inhibitor
-
US regulatory status: approved. Molecular target: Mu-type opioid receptor.
- Target
- Mu-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
Development asset linked to ELITE PHARMACEUTICALS INC in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Muscle-type nicotinic acetylcholine receptor.
- Target
- Muscle-type nicotinic acetylcholine receptor
- Mechanism
- Muscle-type nicotinic acetylcholine receptor antagonist
-
US regulatory status: approved. Molecular target: D2-like dopamine receptor.
- Target
- D2-like dopamine receptor
- Mechanism
- D2-like dopamine receptor agonist
-
Development asset linked to ELITE PHARMACEUTICALS INC in public FDA and regional records.
-
Development asset linked to ELITE PHARMACEUTICALS INC in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-1.
- Target
- Adrenergic receptor alpha-1
- Mechanism
- Adrenergic receptor alpha-1 antagonist